Indeed, some GLP-1 receptor agonists have been shown to reduce incidence of cardiovascular death, non-fatal myocardial infarction, non-fatal cerebral infarction, and impaired renal function in high-risk T2D patients [12,13]. Here, GLP1R is linked to type 2 diabetes mellitus.